肠道菌群
生物
FGF19型
骨骼肌
失调
法尼甾体X受体
内分泌学
细胞生物学
内科学
成纤维细胞生长因子
生物化学
受体
核受体
转录因子
医学
基因
作者
Yixuan Qiu,Jiaming Yu,Yi Li,Fan Yang,Huiyuan Yu,Mengjuan Xue,Fan Zhang,Xin Jiang,Xueying Ji,Zhijun Bao
标识
DOI:10.1080/07853890.2021.1900593
摘要
Background: Recent evidence indicates that host-gut microbiota crosstalk has nonnegligible effects on host skeletal muscle, yet gut microbiota-regulating mechanisms remain obscure.Methods: C57BL/6 mice were treated with a cocktail of antibiotics (Abx) to depress gut microbiota for 4 weeks. The profiles of gut microbiota and microbial bile acids were measured by 16S rRNA sequencing and ultra-performance liquid chromatography (UPLC), respectively. We performed qPCR, western blot and ELISA assays in different tissue samples to evaluate FXR-FGF15/19 signaling.Results: Abx treatment induced skeletal muscle atrophy in mice. These effects were associated with microbial dysbiosis and aberrant bile acid (BA) metabolism in intestine. Ileal farnesoid X receptor (FXR)-fibroblast growth factor 15 (FGF15) signaling was inhibited in response to microbial BA disturbance. Mechanistically, circulating FGF15 was decreased, which downregulated skeletal muscle protein synthesis through the extracellular-signal-regulated protein kinase 1/2 (ERK1/2) signaling pathway. Treating Abx mice with FGF19 (human FGF15 ortholog) partly reversed skeletal muscle loss.Conclusions: These findings indicate that the BA-FXR-FGF15/19 axis acts as a regulator of gut microbiota to mediate host skeletal muscle.
科研通智能强力驱动
Strongly Powered by AbleSci AI